BMS 938790

Drug Profile

BMS 938790

Alternative Names: BMS938790

Latest Information Update: 08 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adnexus Therapeutics
  • Developer Bristol-Myers Squibb
  • Class Anti-inflammatories; Fibronectins; Polyethylene glycols; Proteins
  • Mechanism of Action Interleukin 23 stimulants; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation

Most Recent Events

  • 15 Mar 2015 Pharmacokinetic, pharmacodynamic and adverse event data from a phase I trial in healthy volunteers released by Bristol-Myers Squibb
  • 01 Feb 2015 Phase-I clinical trials in Inflammation (In volunteers) in USA before February 2015 (IV, SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top